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HIV-1 Group O Virus Identified
for the First Time in the United States
In 1994, seven unusual cases of HIV infection
were identified in France (1). These cases occurred
in foreign nationals whose specimens had atypical
Western blot patterns and weak or no seroreactivity
in HIV-1 peptide or recombinant-based enzyme im-
munoassays (EIA). In previous cases, such isolates
had been loosely grouped as phylogenetic outliers,
termed Group O strains, highly divergent from the
Group M strains that gave rise to the HIV-1
pandemic (2). The 1994 cases were soon recognized
as representing the global emergence of genetically
distinct viruses known to be circulating in Cameroon
and Gabon. This recognition prompted an immedi-
ate reassessment of HIV screening in Europe and
North America. Subtype B strains of HIV-1 predomi-
nate in Europe and North America, and there has
been increasing evidence for the entry of non-B
strains into these populations through persons who
were infected while abroad. However, there was no
evidence of indigenous spread of the strains in North
America (3,4).
We report here the laboratory findings related
to the first documented HIV-1 Group O infection in
the United States. The case was identified in April
of this year through the CDC sentinel surveillance
program for unusual HIV variants and involves a
West-Central African woman (residing in the United
States), with a 2-year clinical history of lymph-
adenopathy, thrombocytopenia, and progressive CD4
lymphocyte loss. In February 1995, the patient was
tested for HIV-1-specific antibodies and was deter-
mined to be seronegative (Abbott HIV-1/2; signal/
cutoff value = 0.7) by recombinant-antigen based
EIA.  The patient's serostatus was reevaluated the
following October and November and again in April
of 1996 with inconclusive results (Table 1). On these
occasions, whole virus lysate-based EIAs yielded
negative or weakly positive results (signal/cutoff
ratios were 0.68 to 4.20);  however, confirmatory
Western blot assays remained indeterminate. The
November 1995 sample was negative in both Ge-
netic Systems formats; however, a signal/cutoff ratio
of 0.89 was noted. The Western blot pattern re-
mained remarkably stable through the year, and the
patient's sera remained HIV-1 antigen–negative on
each sampling occasion. Attempts by commercial
reference laboratories to amplify proviral sequences
from the patient's peripheral blood mononuclear
cells by standard Group M gag-specific primers for
polymerase chain reaction (PCR) or reverse tran-
scriptase (RT)-PCR did not show HIV sequences.
To reconcile the serologic findings, a panel of HIV
subtype–specific, peptide-based EIAs was performed
at CDC (6) (Table 2). As points of reference, examples
of results with sera representing the Group M sub-
types A, B, C, D, E, and F are shown. A high degree
of cross-reactivity exists among the Group M sera,
with the strongest response usually directed against
the V3 peptide from the subtype that infected the
source patient. The exception to this (Table 2) is seen
in the Brazilian subtype F sera, which react strongly
with the subtype B peptide but not with the sub-
type F peptide, which was derived against subtype
F isolates from Romania. The distinction between
Brazilian and Romanian sera is reflected in the ge-
netic diversity between isolates from the two regions
(7). This broad seroreactivity among group M sera
is also reflected in their response to group-specific
peptides from the gp41. However, the patient's sera
were only reactive to the Group O–specific V3 and
gp41 peptides (OD = 1.704 and 2.467, respectively).
This provided the first direct evidence that this pa-
tient was infected with a Group O variant.
The virus CDC7755 was isolated by cocultivating
the patient's peripheral blood mononuclear cells
with phytohemagglutinin A, which stimulated nor-
Genetic Genetic     OTC   Abbott Abbott
Systems Systems    HIV-1   HIV-1 HIV-1/2
Sample date HIV-1 EIAa HIV-1/2 EIAa     EIAa     EIAa   EIAa
February 1995 ND ND ND ND   0.70
October 1995a   0.51   1.35 ND ND ND
November 1995b   0.41   0.89 ND ND ND
April 1996c   4.20   3.40   0.68   3.10   1.15
aHIV-1 WB = indeterminate; detected p17, p24, p31, p50, p66, and equivocal gp41; HIV-1
     antigen = negative (0.40).
bHIV-1 WB = same as above; HIV-1 antigen = negative (0.34).
cHIV-1 WB = same as above; HIV-1 IFA = positive (2.5+).
ND = not done.
Table 1. Results of enzyme immunoassay for antibodies to HIV
mal human peripheral blood mono-
nuclear cells. Viral replication was
monitored by antigen capture (Coulter
SIV Core Antigen Assay, Hialeah, FL)
and PCR amplification of the viral pro-
tease gene (8). Virus growth was rapid,
highly cytolytic, and characterized by
punctate syncytial formation through-
out the primary culture. All PCR
amplifications were performed with
hotstart technology and nested primer
sets to facilitate direct sequencing. AEmerging Infectious Diseases Vol. 2, No. 3—July-September 1996
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consensus set of nested primers, which is generic
for Group M viruses, was first used to attempt am-
plification and detection of the viral protease. This
set did not detect proviral sequences during direct
evaluation of the patient's peripheral blood mono-
nuclear cells; however, a comparably derived
consensus primer set for the Group O proteases
readily amplified proviral sequences from the
patient's cells and cocultures.
For sequence comparison and phylogenetic analy-
sis, proviral sequences spanning the viral protease
gene and portions of the p24 and gp120 gene re-
gions were amplified from the patient's peripheral
blood mononuclear cells and cocultures.1 Amplifica-
tion of a 738-bp fragment spanning the junction of
the p24 and p17 genes of the gag region was accom-
plished through a nested set of generic primers (9).
Group O consensus primer sets were derived to
amplify the 297-bp viral protease gene and a 381-
bp fragment spanning the C2V3 portion of gp120
within the env gene. Sequence identity was demon-
strated between repeated patient samplings and
successive days in cocultivation for each of the gag,
pol, and env elements, thus confirming a common
but unique source for the isolate. For phylogenetic
analysis, these sequences were further edited to
obtain the relevant portions of the protease gene
(254 bp), p24 (419 bp), and C2V3 region( 233 bp) of
gp120. Phylogenetic analysis was performed by
neighbor-joining and maximum-likelihood methods
(10,11).
In the phylogenetic analysis of the protease gene,
we included the two available Group O prototypes
(ANT70 and MVP5180), reference strains for the
HIV-1 subtypes representing Group M variants, and
HIV-2 strains (Figure 1A).  The fidelity of the phy-
logenetic results was verified by boot
strap analysis (100 data sets) and
pruning, i.e., the sequential removal
of representative strains followed by
reanalysis. The segregation of
CDC7755 and Group O strains was
absolute and is consistent with a di-
vergence independent of the rooting
of the Group M clades (Figure 1A).
For each gene region, all resulting
trees were consistent with the exclu-
sion of the CDC7755 isolate from the
Table 2.   Typical peptide reactivity patterns.
Subtype V3-A V3-B V3-C V3-D V3-E V3-F V3-O GP41-M GP41-O
A 2.742 1.144 1.628 0.065 0.083 0.724 0.055 2.683 2.627
B 0.071 1.271 0.051 0.030 0.033 0.038 0.028 2.570 2.414
C 2.320 0.084 2.515 0.079 1.647 1.637 0.061 2.746 2.858
D 0.210 0.079 0.056 1.203 0.048 0.051 0.040 1.380 0.279
E 0.055 0.043 0.385 0.042 1.291 0.038 0.025 0.619 0.340
F 0.062 0.657 0.041 0.037 0.039 0.033 0.037 2.615 2.670
O 0.089 0.088 0.089 0.188 0.088 0.081 1.704 0.070 2.457
GP41-M and GP41-O refer to peptides derived from the consesus gp41 sequences for
Group M and Group O variants.
Group M family and its strong inclusion with the
Group O strains.
To better understand the evolutionary relation-
ship between the patient s strain and other Group
O isolates, we analyzed the C2V3 region of gp120
from multiple Group O strains. This gene region
exhibits a high degree of divergence and has been
sequenced for the largest number of Group O vari-
ants (Figure 1B). The chimpanzee isolate SIV-CPZ
was used as an outgroup.  We took this approach to
avoid possible errors introduced through an align-
ment of very distant HIV-1 and HIV-2 strains. Our
findings indicate that strain CDC7755 retains a dis-
tant evolutionary relationship to the MVP5180
isolate (Figure 1B, MVP51) yet represents a distinct
evolutionary lineage within Group O. The nucleotide
sequence divergence among the represented strains
is 19% to 26%, values characteristic of Group O vi-
ruses and typical of intersubtype rather than
intrasubtype genetic distances among the Group M
variants. This level of diversity among the Group O
members emphasizes the potential that the limited
number of “O” variants yet recognized may repre-
sent a set of genetic lineages as distinct as the Group
M subtypes.
An alignment of the deduced C2V3 amino acid
sequence of strain CDC7755 with those of three
Cameroonian Group O reference strains is presented
in Figure 2; the V3 loop is bound by the two cys-
teine residues (residues 45 and 83). Unlike Group
M viruses, which show greater heterogeneity in the
regions flanking the V3 loop, the Group O viruses,
including the CDC7755 strain, show substantial di-
vergence within the loop itself. The pattern of
potential N-glycosylation sites over the C2V3 region
of the CDC7755 strain is consistent with that found
1Primers: gag/outer/forward - AGTACATGTTAAAACATGTAGTATGGGC; gag/outer/ reversed - CCTACTCCCTGACAGGCCGT
CAGCATTTCTTC; gag/inner/forward - AGTACATGTTAAAACATGTAGTATGGGC; gag/inner/reverse - CCTTAAGCTTTTGT
AGAATCTATCTACATA; protease/outer/forward - TTTGCCTCCCTCAAATC; protease/outer/reverse - TTACTGGCACTG GGGCTATGG;
protease/inner/ forward - CCTCAAATCCCTCTTTG; protease/inner/reverse - TATAGGGAAGTTTAGTGTACA;  env/outer/forward -
CACAGAATTTAATGGAACAGGC; env/outer/reverse - TGTGTT ACAATAAAAGAATTCTCC;  env/inner/forward -
GTTACTTGTACACATGGCAT; and env/inner/reverse - AGAATTCTCCATGACAGTTAAA.Vol. 2, No. 3—July-September 1996 Emerging Infectious Diseases
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Figure 1. Phylogenetic analysis of the prt and env gene sequences. The patient's isolate is indicated by the arrow.
The trees were constructed on the basis of the proviral DNA sequences for the protease gene (A) by the neighbor-
joining method in the Phylip 3.5c package (2) and 230 aligned nucleotides from the C2V3 region of the env gene
of Group O isolates (B) by using the maximum likelihood method with the fast DNAml program (1). Numbers at
the branch nodes within the protease tree indicate bootstrap values. The SIV-MM251 protease gene sequence
and the SIV-CPZ env sequence were used as outgroups in trees A and B, respectively. The nucleotide sequence
distance among strains can be deduced from the horizontal branch lengths by using the included bar scale.
Vertical distances are for clarity only.
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Figure 2. Alignment of deduced amino acid sequences of the env C2V3 region of the CDC7755 strain with those
of three representative Group O Cameroonian strains (ANT70C, MVP5180 and FR.VAU).  The CONS.O repre-
sents the consensus amino acid sequence derived from the four strains presented in this alignment. (?) represents
positions where a consensus could not be derived. (-) indicates identical amino acids with the CONS.O and (*)
indicates gaps (insertion\deletions) that were introduced to align the sequences.
among the Group O reference strains. Also of inter-
est is the increased number of amino acid residues
in the V3 loop of the CDC7755 strain (37 amino
acids)–a feature common to other Group O viruses
but two to three residues more than most Group M
viruses; however, the significance of these differ-
ences is not clear.
To date, nearly all of the Group O infections re-
ported worldwide (fewer than 100), have been
detected in persons from West-Central Africa. This
is the first Group O case reported in the United
States, and the presence of these infections here is
believed to be exceedingly low. However, the discov-
ery of any divergent HIV strains should be
considered a sentinel event and should prompt the
reappraisal of HIV antibody tests used to protect of
the blood supply. In  the United States guidelines
for preventing HIV transmission by blood and blood
products include testing for HIV-1 and -2; the re-
finements necessary to improve the sensitivity ofEmerging Infectious Diseases Vol. 2, No. 3—July-September 1996
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these diagnostic  tests for the detection of Group O
variants are known. Other criteria for donor defer-
ral (e.g., self-deferral for donors at high risk for HIV
infection and temporary exclusion of donors from
malaria-endemic regions) that may confer a mea-
sure of protection against divergent HIV viruses
present in equatorial Africa are in place. The iden-
tification of Group O infections underscores the
potential for the emergence of other highly diver-
gent HIV strains and highlights the importance of
maintaining active worldwide surveillance for these
variants.
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